Home›Companies›Biotech & Pharma›DeepCyte

DeepCyte Inc.

AI tools help drug developers predict and understand toxicity in human cells.

Updated Nov 16, 2026·Latest SEC filing Jan 29, 2026·Suggest an edit

About DeepCyte

DeepCyte is a private company based in Wilmington, Delaware, incorporated in 2025 in Delaware. It has reported $1,445,536 raised in one offering on Form D since January 2026. Its chief executive is Theodore Alexandrov.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Jan 15, 2026Jan 29, 2026$1,445,536of $1.7M target10$144KEquityRule 506(b)Form D ↗

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on DeepCyte's Form D filed Jan 29, 2026.

Sources

  1. SECDeepCyte Inc. filing history
  2. CompanyDeepCyte privacy policy
  3. CompanyDeepCyte seed announcement